Regencell Bioscience (NASDAQ:RGC) Trading Down 7.8% – Should You Sell?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares were down 7.8% during mid-day trading on Tuesday . The company traded as low as $24.50 and last traded at $25.30. Approximately 103,945 shares traded hands during mid-day trading, a decline of 91% from the average daily volume of 1,208,313 shares. The stock had previously closed at $27.43.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Regencell Bioscience Stock Up 40.4%

The stock has a 50 day moving average price of $21.52 and a 200 day moving average price of $17.19.

Institutional Investors Weigh In On Regencell Bioscience

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC acquired a new position in shares of Regencell Bioscience in the 2nd quarter worth approximately $1,701,000. Geode Capital Management LLC boosted its holdings in Regencell Bioscience by 5,637.5% during the second quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock worth $6,664,000 after buying an additional 384,250 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in Regencell Bioscience in the second quarter worth approximately $222,000. XTX Topco Ltd acquired a new position in Regencell Bioscience in the third quarter worth approximately $598,000. Finally, BNP Paribas Financial Markets bought a new position in shares of Regencell Bioscience in the second quarter valued at $768,000. 0.13% of the stock is owned by institutional investors and hedge funds.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.